CRISPR/Cas9 library screening reveals that STK19 has synergistic antitumor effects when combined with cisplatin on tongue squamous cell carcinoma.

ABSTRACT:

Background

Tongue squamous cell carcinoma (TSCC) is a common oral cancer that has a high propensity for recurrence and metastasis. Therefore, TSCC has a 50% 5-year survival rate. Platinum-based chemotherapy is an effective treatment for squamous cell carcinoma, however, chemotherapy resistance remains a major issue. Therefore, innovative and effective drug combinations are needed to improve TSCC patient prognosis.

Methods

In this study, we conducted an in vitro CRISPR/Cas9 library screen using two TSCC cell lines (Tscca and Cal27) to identify specific genes that, when inhibited, synergize with cisplatin to effectively suppress tumor growth.

Results

We identified STK19 as a potential drug target. Inhibition of STK19 enhances the response of TSCC to cisplatin. Through g

SUBMITTER: Li C 

PROVIDER: S-EPMC12538773 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature